Information for Colorado Prescribers of Prescription Drugs XCOPRI® (cenobamate tablets) CV • The following information is be
![These highlights do not include all the information needed to use XCOPRI safely and effectively. See full prescribing information for XCOPRI. XCOPRI® (cenobamate tablets), for oral use, CV Initial U.S. Approval: 2020 These highlights do not include all the information needed to use XCOPRI safely and effectively. See full prescribing information for XCOPRI. XCOPRI® (cenobamate tablets), for oral use, CV Initial U.S. Approval: 2020](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=cenobamate-06.jpg&id=674551)
These highlights do not include all the information needed to use XCOPRI safely and effectively. See full prescribing information for XCOPRI. XCOPRI® (cenobamate tablets), for oral use, CV Initial U.S. Approval: 2020
Arvelle Announces European Medicines Agency Acceptance of the Marketing Authorization Application (MAA) for Cenobamate The MAA s
![Latest XCOPRI® (cenobamate tablets) CV Post-hoc Analysis Presented at the 75th American Academy of Neurology Annual Meeting Latest XCOPRI® (cenobamate tablets) CV Post-hoc Analysis Presented at the 75th American Academy of Neurology Annual Meeting](https://mma.prnewswire.com/media/2054730/SK_Life_Science_Logo.jpg?p=publish)